Syndax Pharmaceuticals Inc (SNDX)

Syndax Pharmaceuticals Inc (SNDX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.2B; returns 1 day -1.3%, 1 week +3.9%, 1 year -8.7%.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for cancer. The company's revenue model is based on its two FDA-approved oncology drugs. The primary revenue driver is Revuforj (revumenib), a first-in-class menin inhibitor for which Syndax records direct net product sales.

Groups SNDX belongs to

• Biotechnology
• Oncology
• Commercial Stage
• Commercial Stage Biotech
• Healthcare
• Pharmaceuticals
• Precision Medicine
• Hematologic Malignancies
• Monoclonal Antibodies

SNDX financial model: income statement, cash flow and balance sheet